Keyphrases
Neurofibromatosis Type I
100%
Precision Medicine
100%
Neurofibromatosis
100%
Selumetinib
100%
MEK Inhibitor (MEKi)
100%
Neurofibromatosis Type 1 (NF-1)
100%
Medicines Development
100%
Targeted Therapy
25%
Plexiform Neurofibroma
25%
Combination Therapy
12%
Cell Signaling
12%
Swine Model
12%
Low-grade Glioma
12%
FDA-approved Drugs
12%
Neoplasms
12%
Related Conditions
12%
Common Cause
12%
Malignant Neoplasms
12%
Benign Neoplasm
12%
Genomic Signals
12%
Signal Alteration
12%
Associated Pathologies
12%
Preclinical Animal Models
12%
Medicine and Dentistry
Personalized Medicine
100%
Neurofibromatosis Type I
100%
MEK Inhibitor
100%
Neurofibromatosis
100%
Selumetinib
100%
Targeted Therapy
25%
Plexiform Neurofibroma
25%
Malignant Neoplasm
12%
Combination Therapy
12%
Neoplasm
12%
Ganglioglioma
12%
Translating (Language)
12%
Benign Tumor
12%
Signal Transduction
12%